BPC-157 and TB-500 are two of the most-studied research peptides in regenerative biology and tissue repair research. Despite often being discussed together (and sometimes sold as a stack), they are distinct compounds derived from different proteins with different proposed mechanisms. This page covers the structural differences, signaling pathways, and research use cases for each.
All compounds referenced are for research purposes only. Not for human use.
Quick Reference
| Property | BPC-157 | TB-500 |
|---|---|---|
| Source protein | Body Protection Compound (gastric protein) | Thymosin Beta-4 (cytoskeletal protein) |
| Amino acids | 15 | 43 (fragment of TB-4) |
| Molecular weight | 1,419.53 Da | ~4,963 Da |
| Sequence | GEPPPGKPADDAGLV | LKKTETQEKNPLPSKETIEQEKQAGES (active fragment) |
| Proposed primary pathway | Nitric oxide system (eNOS upregulation) | Actin sequestration / G-actin binding |
| Research applications | Tendon repair, angiogenesis, gut models | Wound healing, cardiac, anti-inflammatory |
| LLR availability | 10mg ($89) | Various sizes |
BPC-157 — Structure and Proposed Mechanisms
BPC-157 (Body Protection Compound 157) is a 15-amino acid synthetic pentadecapeptide derived from a protein found in human gastric juice. The “157” designates its position in the original protein isolate. In research models, the proposed mechanisms include:
- Nitric oxide system: reported upregulation of eNOS in endothelial cells, potentially via FAK-paxillin signaling
- VEGF pathway: associated with angiogenesis observations in wound healing models
- Fibroblast signaling: in vitro studies show effects on fibroblast migration and proliferation, relevant to tendon and ligament repair models
- Dopaminergic / serotonergic systems: CNS studies in rodent models
The majority of BPC-157 research is preclinical (cell culture and rodent models).
TB-500 — Structure and Proposed Mechanisms
TB-500 is the synthetic active fragment of Thymosin Beta-4 (TB-4), a 43-amino acid naturally-occurring cytoskeletal protein abundant in platelets and many tissues. The “500” is an arbitrary numbering. In research models, the proposed mechanisms include:
- G-actin sequestration: TB-500 binds monomeric G-actin, regulating actin polymerization — central to cell migration, cytoskeletal remodeling, and wound healing
- Anti-inflammatory signaling: reduced inflammatory cytokine production in some models
- Angiogenesis: similar to BPC-157, reported angiogenic effects but through a different molecular pathway
- Cardiac research: TB-4 (parent protein) has been studied in cardiomyocyte protection and regeneration models
Research Use Case Matrix
| Research Question | Preferred Compound | Rationale |
|---|---|---|
| Nitric oxide / eNOS pathway | BPC-157 | Primary proposed mechanism |
| Actin cytoskeleton studies | TB-500 | G-actin binding is TB-500’s defining mechanism |
| Tendon / ligament repair models | BPC-157 | Stronger preclinical literature base for connective tissue |
| Wound healing (skin, epithelium) | Either | Different molecular routes; comparative studies common |
| Cardiac protection models | TB-500 | Parent protein TB-4 has stronger cardiac literature |
| Gastrointestinal mucosal research | BPC-157 | Originally isolated from gastric protein |
| Comparative angiogenesis | Both (head-to-head) | Different signaling pathways producing similar phenotype — interesting study design |
Combining BPC-157 + TB-500 in Research
Some research designs use BPC-157 and TB-500 in combination based on the hypothesis that their different mechanistic angles produce additive effects on tissue repair. Whether the combination shows true synergy versus additivity is an open question in preclinical literature — and a reasonable research design for in vitro or rodent comparative studies.
For combined-use research, source both compounds from a vendor with verified third-party COAs to control for purity confounds. Mismatched documentation between the two compounds introduces variables that complicate interpretation.
Purity Requirements
Both BPC-157 and TB-500 are smaller and simpler to synthesize than GLP-1 peptides — but both are still subject to synthesis-quality variability that affects research validity:
- HPLC purity: ≥98% for both
- Mass spectrometry confirmation: BPC-157 at 1,419.53 Da; TB-500 at ~4,963 Da
- Endotoxin (LAL): critical for cell culture work; <1 EU/mg
- Third-party COA: not vendor-internal
Life Link Research provides six-panel third-party independent COAs for both compounds, available before purchase.
Frequently Asked Questions
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino acid peptide derived from a gastric protein; TB-500 is a 43-amino acid fragment of Thymosin Beta-4, a cytoskeletal protein. Different source, different size, different proposed mechanisms (NO system vs actin sequestration).
Can BPC-157 and TB-500 be used together?
Some research designs combine them based on the hypothesis that different mechanistic angles produce additive effects. Whether the combination shows true synergy is an open research question.
Which has stronger preclinical literature?
BPC-157 has broader preclinical literature in tendon/ligament repair specifically. TB-500’s parent protein (Thymosin Beta-4) has stronger literature in cardiac and wound-healing contexts.
What purity should research-grade BPC-157 or TB-500 be?
≥98% by HPLC, with mass spectrometry confirmation. Third-party independent testing preferred over vendor-internal assays.
For research purposes only. Not for human use.